Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

BACKGROUND: Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Agnello, Lisa, Tortorella, Silvia, d’Argenio, Annachiara, Carbone, Clarissa, Camorani, Simona, Locatelli, Erica, Auletta, Luigi, Sorrentino, Domenico, Fedele, Monica, Zannetti, Antonella, Franchini, Mauro Comes, Cerchia, Laura
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8299618/
https://ncbi.nlm.nih.gov/pubmed/34294133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-021-02039-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados